Photocure establishes US subsidiary to build speciality dermatology business
(Thomson Reuters ONE) -
OSLO, Norway, 4 August 2010: Photocure (OSE: PHO), a Norwegian pharmaceutical
company specialising in dermatology and cancer, today announce the establishment
of its US subsidiary, Photocure Inc, and the appointment of Terry Conrad as
President to build its specialty dermatology business in the US.
Terry Conrad has over 23 years experience in the pharmaceutical industry and has
held senior marketing, sales and business development positions at a number of
multinational pharmaceutical companies including Lederle Laboratories, Bayer AG
and Parke-Davis (a division of Warner Lambert now owned by Pfizer). He was most
recently President and CEO of Merz Pharmaceuticals GmbH-US division. During his
time at Merz, Terry was responsible for managing US commercial operations and
building the dermatology franchise while also preparing for two new business
units. Revenues at Merz US more than tripled during his tenure to over US$70
million while also delivering significant profitability. He has a successful
track record of launching products in various specialties and his last 10 years
in the dermatology field will be a valuable asset to Photocure as it enters the
US market.
The establishment of Photocure Inc follows the Company's strategic decision in
November 2009 to build its own specialty dermatology business in the US.
Photocure is using its proven photodynamic technology (PDT) and expertise to
develop innovative dermatology products. PDT is a well established procedure in
the dermatology field, and Photocure has been a leader in developing effective
PDT products to serve that market.
Photocure is developing Allumera(TM), a novel PDT-based solution for improving
the appearance of skin. Allumera is currently undergoing a pilot consumer trial
in the US. Results from this consumer trial are expected in the fourth quarter
2010. Based on results from previous clinical trials, the company believes
Allumera(TM) will be well accepted by the dermatology community. Photocure is
planning to launch Allumera in 2011.
Also, Photocure is developing Visonac(TM), an exciting new option for treating
moderate to severe acne. Visonac is currently in Phase II development.
Kjetil Hestdal, M.D. Ph.D, President and CEO of Photocure, said:
"We are delighted that Terry has joined Photocure to spearhead our expansion
into the US. His track record of success in launching products combined with
his knowledge and experience of the US dermatology market, will be instrumental
in successfully building our operations in the US."
Terry Conrad, President of Photocure Inc, said:
"Photocure has an exciting pipeline of medical dermatology and aesthetic
products offering clinical and technical advantages over existing products on
the market. This is an exciting time to build Photocure's operations and sales
capabilities in the US. The launch of Allumera(TM) into the US market will
enable Photocure to enter the attractive skin rejuvenation market segment and
provide the platform for growing our dermatology business."
-ends-
For further information, please contact
President & CEO Kjetil Hestdal, Tel: + 47 913 19 535, email: kh(at)photocure.no
CFO Christian Fekete, Tel: + 47 916 42 938 email: cf(at)photocure.no
President Photocure Inc, Terry Conrad, Tel: + 1 336 681 8777
Mary Clark, Capital MS&L, Tel: +44 207 307 5330 email: mary.clark(at)capitalmsl.com
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock
Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical
devices for the photodynamic treatment and diagnosis of cancer and selected
dermatology indications.
Photocure's commercial activities include its own marketing and sales
organisations in selected markets as well as partnerships with leading
pharmaceutical companies on a regional or global basis.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for
the diagnosis of bladder cancer. Hexvix® is approved in EU and in the US. In
addition, the company has developed a proprietary light source, which is used in
combination with Visonac(TM) cream. Through worldwide studies, Photocure is
continuously testing its products for new indications, and the aim is to develop
a pipeline of follow-on products based on the Photocure Technology(TM) platform.
For more information about Photocure, visit our website at www.photocure.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1435795]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Photocure ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 04.08.2010 - 13:04 Uhr
Sprache: Deutsch
News-ID 38672
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Photocure establishes US subsidiary to build speciality dermatology business"
steht unter der journalistisch-redaktionellen Verantwortung von
Photocure ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
